Analysts are intrested in these 5 stocks: ( ($IBIO) ), ( ($RLMD) ), ( ($SEE) ), ( ($OLLI) ) and ( ($IVVD) ). Here is a breakdown of their recent ...

The Saudi Food and Drug Authority (SFDA) has approved Qfitlia (Fitusiran) for the prevention or reduction of bleeding episodes in adults and adolescents aged 12 and above with hemophilia A or B, ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

RNA interference (RNAi) is a biotechnological tool used for gene silencing in plants, with both endogenous and exogenous applications. Endogenous approaches, such as host-induced gene silencing (HIGS) ...

ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...